HIV news from aidsmap.com

French study confirms efficacy of on-demand PrEP
Eight years after it started, the final results of a large French study that offered a choice of daily or event-driven oral PrEP (using tenofovir disoproxil/emtricitabine) were presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, US yesterday.
>> Read more

The war on science: resisting and rebuilding at a crucial juncture
Peter Staley’s talk at the opening session of the Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver was a grim post-mortem of one of the most challenging years in recent HIV history – an ‘annus horribilis’ – a phrase Queen Elizabeth II used to describe 1992 and The Lancet applied to 2025.
>> Read more

CD8 cell fitness predicts who benefits most from antibody-based cure strategies
Over the last few years a number of studies aiming to cure HIV or at least achieve long-term viral suppression off antiretroviral therapy (ART) have produced tantalising results. These studies have given participants one or both of the long-acting versions of two broadly neutralising antibodies (bnAbs), 3BNC117 (teropavimab) and 10-1074 (zinlirvimab), sometimes in conjunction with immune boosting oral drugs.
>> Read more